Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VESPA: Varenicline for Excessive Daytime Sleepiness in Parkinson's Disease
NCT02473562Phase 4Terminated
- Sponsor
- Amsterdam University Medical Center
- Start
- May 2013
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Parkinson's disease (PD) comparing Varenicline with Placebo (2 arms). Primary endpoint: Daytime sleepiness at 4 weeks. Started May 2013; status: terminated.
02
Drugs
varenicline
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02473562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02473562.